Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Artificial Intelligence (AI) For De Novo Drug Design Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The artificial intelligence (AI) for de novo drug design market has seen a significant increase in its size over recent years. It is projected to grow from $1.9 billion in 2025 to $2.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 33.4%. The historical expansion can be attributed to factors such as elevated research and development costs in traditional drug discovery, a rising need for expedited drug development, the adoption of computational chemistry tools, increased pharmaceutical investments, and broader academic and research collaborations.
The artificial intelligence (AI) for de novo drug design market is anticipated to experience substantial growth in the coming years. It is projected to reach $8.07 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 33.7%. This expansion during the forecast period is propelled by factors such as the increasing integration of AI for lead compound generation, a rising utilization of ADMET prediction models, the growing convergence of cloud and on-premises deployment, the broadening of model development and data annotation services, and enhanced collaboration between pharmaceutical and biotech companies. Significant trends for the forecast period include the increasing adoption of cloud-based AI platforms, a surge in demand for deep learning-based drug design software, the progressive incorporation of workflow automation in drug discovery, the expansion of molecular property prediction tools, and an intensified focus on targeted therapeutic area applications.
Get A Free Sample Report With In-Depth Market Insights:
Artificial Intelligence (AI) For De Novo Drug Design Market Growth Factors Behind Sustained Expansion
The escalating occurrence of complex diseases is anticipated to drive the expansion of artificial intelligence (AI) for the de novo drug design market in the coming years. Complex diseases are medical conditions resulting from a mix of genetic, environmental, and lifestyle elements, frequently impacting multiple bodily systems and necessitating sophisticated or extended medical care. The rise in these diseases is linked to unhealthy lifestyle choices, which elevate the likelihood of chronic illnesses like diabetes, cardiovascular diseases, and specific cancers. Artificial intelligence (AI) in de novo drug design facilitates the identification of new treatments by examining intricate biological information and forecasting promising drug candidates, thereby tackling the difficulties presented by complex, multifactorial, and chronic conditions. As an illustration, in February 2024, the World Health Organization, an international body situated in Switzerland, projected over 35 million new cancer cases by 2050, indicating a 77% increase relative to the estimated 20 million cases reported in 2022. Consequently, the growing incidence of complex diseases is fueling the development of the artificial intelligence (AI) for de novo drug design market.
Artificial Intelligence (AI) For De Novo Drug Design Market Segment Breakdown: Which Categories Lead On Revenue?
The artificial intelligence (AI) for de novo drug design market covered in this report is segmented –
1) By Component: Software, Services
2) By Therapeutic Area: Oncology, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases, Rare Diseases, Metabolic Disorders, Other Therapeutic Areas
3) By Deployment Mode: On-Premises, Cloud-Based
4) By Application: Target Identification, Lead Compound Generation, Molecular Property Prediction, Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction), Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End Users
Subsegments:
1) By Software: Cloud Based Software, On Premise Software, Machine Learning Software, Deep Learning Software, Molecular Modeling Software, Data Analytics Software, Workflow Automation Software
2) By Services: Consulting Services, Integration Services, Maintenance And Support Services, Training And Education Services, Managed Services, Data Annotation Services, Model Development Services
Artificial Intelligence (AI) For De Novo Drug Design Market Industry Trends Fueling Future Revenue Growth
Leading companies operating within the artificial intelligence (AI) for de novo drug design market are concentrating on developing innovative solutions, such as AI-native drug discovery platforms, to accelerate the design and optimization of novel small molecules. These artificial intelligence (AI)-native drug discovery platforms are integrated systems that utilize AI models to generate, predict, and select new molecules from the ground up, thereby speeding up drug discovery by identifying promising compounds more quickly and efficiently than traditional trial-and-error methods. For example, in November 2025, Terray Therapeutics, a US-based biotechnology company, introduced EMMI (Experimentation Meets Machine Intelligence), an AI-native drug discovery platform specifically engineered for de novo small molecule design. This platform integrates Terray’s proprietary ultra-miniaturized experimental hardware with a highly automated laboratory and the Chemistry-Oriented AI Transformer Interface, third generation (COATI3) chemistry foundation model, to generate millions of novel molecules, predict their potency, select the most promising candidates, and iteratively optimize them. The platform’s generative AI employs reinforcement learning to propose synthetically accessible molecules, while predictive AI models rapidly evaluate properties like potency, selectivity, solubility, metabolism, and clearance, and the selection AI optimizes which molecules to synthesize to reduce time and cost by up to threefold compared to industry standards. EMMI is applicable across internal immunology programs as well as partnerships targeting previously unexplored chemical space, establishing it as a transformative tool for de novo drug design.
Artificial Intelligence (AI) For De Novo Drug Design Market Key Participants And Competitive Landscape
Major companies operating in the artificial intelligence (AI) for de novo drug design market are Schrödinger Inc., XtalPi Holdings Ltd., Owkin Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd., Generate Biomedicines Inc.
View The Full Artificial Intelligence (AI) For De Novo Drug Design Market Report:
Artificial Intelligence (AI) For De Novo Drug Design Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the artificial intelligence (AI) for de novo drug design market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) for de novo drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
